Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 03:44PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.13 Insider Own1.10% Shs Outstand50.77M Perf Week-0.77%
Market Cap3.40B Forward P/E83.20 EPS next Y0.80 Insider Trans-15.95% Shs Float50.44M Perf Month-2.98%
Income-6.09M PEG- EPS next Q-0.06 Inst Own99.35% Short Float6.82% Perf Quarter-2.02%
Sales366.38M P/S9.28 EPS this Y445.87% Inst Trans3.16% Short Ratio3.75 Perf Half Y26.27%
Book/sh12.56 P/B5.31 EPS next Y93.12% ROA-0.88% Short Interest3.44M Perf Year11.01%
Cash/sh6.76 P/C9.86 EPS next 5Y- ROE-1.01% 52W Range47.59 - 69.68 Perf YTD7.16%
Dividend Est.- P/FCF- EPS past 5Y36.15% ROI-0.92% 52W High-4.30% Beta0.60
Dividend TTM- Quick Ratio8.98 Sales past 5Y541.82% Gross Margin72.46% 52W Low40.12% ATR (14)0.42
Dividend Ex-Date- Current Ratio10.73 EPS Y/Y TTM90.17% Oper. Margin-1.29% RSI (14)35.07 Volatility0.49% 0.48%
Employees797 Debt/Eq0.04 Sales Y/Y TTM33.86% Profit Margin-1.66% Recom2.78 Target Price71.57
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q908.33% Payout- Rel Volume0.35 Prev Close66.47
Sales Surprise2.24% EPS Surprise101.55% Sales Q/Q27.72% EarningsFeb 28 AMC Avg Volume916.14K Price66.68
SMA20-1.78% SMA50-1.87% SMA2009.89% Trades Volume311,586 Change0.32%
Date Action Analyst Rating Change Price Target Change
Jan-09-24Downgrade Wolfe Research Outperform → Peer Perform
Jul-19-23Initiated Robert W. Baird Outperform $69
Jul-13-23Initiated KeyBanc Capital Markets Overweight $70
May-23-23Initiated CL King Buy $75
Apr-14-23Initiated Mizuho Buy $75
Mar-24-23Upgrade Needham Hold → Buy $71
Oct-21-22Initiated RBC Capital Mkts Outperform $85
Oct-12-22Initiated Jefferies Hold $75
Oct-10-22Downgrade Needham Buy → Hold
Apr-06-22Initiated Wolfe Research Outperform $69
Today 06:30AM
Mar-29-24 12:00PM
Mar-22-24 04:01PM
Mar-21-24 04:54PM
Mar-15-24 08:53AM
06:00AM Loading…
Mar-14-24 06:00AM
Feb-29-24 04:01PM
Feb-28-24 07:01PM
Feb-02-24 09:09PM
Jan-31-24 06:30AM
Jan-29-24 11:02PM
Jan-25-24 08:07AM
02:45PM Loading…
Jan-23-24 02:45PM
Jan-10-24 03:07PM
Jan-08-24 07:38PM
Dec-27-23 04:01PM
Nov-20-23 09:55AM
Nov-06-23 12:00PM
Nov-01-23 06:00AM
Oct-31-23 09:27AM
Oct-30-23 05:55PM
04:28PM Loading…
Oct-26-23 10:02AM
Oct-23-23 10:00AM
Oct-16-23 10:23AM
Oct-14-23 01:15PM
Oct-11-23 11:42AM
Oct-02-23 06:00AM
Sep-22-23 11:47AM
Sep-11-23 11:47AM
Aug-25-23 06:00AM
Aug-21-23 06:00AM
Jul-28-23 12:46PM
Jul-27-23 05:25PM
Jun-29-23 06:00AM
May-31-23 10:27AM
May-25-23 09:28AM
May-16-23 02:45AM
May-08-23 09:06AM
May-01-23 05:15PM
Apr-25-23 06:00AM
Apr-24-23 06:00AM
Apr-17-23 03:54PM
Apr-10-23 06:00AM
Mar-29-23 06:00AM
Mar-07-23 06:00AM
Mar-04-23 07:39AM
Mar-01-23 05:25PM
Feb-25-23 02:14PM
Feb-22-23 10:00AM
Feb-08-23 04:30PM
Jan-31-23 06:00AM
Jan-19-23 06:43AM
Jan-12-23 09:19AM
Jan-11-23 06:00AM
Dec-23-22 12:58PM
Dec-22-22 09:03AM
Dec-21-22 06:00AM
Dec-19-22 09:40AM
Dec-13-22 12:40PM
Dec-02-22 09:40AM
Nov-18-22 06:00AM
Nov-16-22 11:06AM
Nov-07-22 12:52PM
Nov-01-22 12:35PM
Oct-31-22 05:15PM
Oct-24-22 10:00AM
Oct-13-22 09:40AM
Oct-09-22 10:20AM
Sep-26-22 09:40AM
Sep-12-22 09:15AM
Sep-08-22 06:00AM
Sep-07-22 09:40AM
Aug-22-22 09:40AM
Aug-18-22 06:00AM
Aug-17-22 06:00AM
Aug-08-22 12:00PM
Aug-05-22 04:34PM
Aug-04-22 09:40AM
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Noblett KarenChief Medical OfficerJan 31 '24Option Exercise0.0027,500045,716Feb 02 05:59 PM
Sama RindaChief Operating OfficerJan 31 '24Option Exercise0.0028,000083,854Feb 02 06:00 PM
Woock JohnEVP, Chief Mktg/Strtgy OfficerJan 31 '24Option Exercise0.0028,000093,302Feb 02 05:59 PM
Ford Alfred J JrChief Commercial OfficerJan 31 '24Option Exercise0.0025,500060,065Feb 02 05:59 PM
Keese Kari LeighChief Financial OfficerJan 31 '24Option Exercise0.006,167046,812Feb 02 05:59 PM
COHEN RAYMOND WChief Executive OfficerJan 31 '24Option Exercise0.0063,4000223,996Feb 02 05:59 PM
COHEN RAYMOND WChief Executive OfficerJan 31 '24Sale67.7435,1612,381,662188,835Feb 02 05:59 PM
Ford Alfred J JrChief Commercial OfficerJan 31 '24Sale67.7416,6151,125,43243,450Feb 02 05:59 PM
Woock JohnEVP, Chief Mktg/Strtgy OfficerJan 31 '24Sale67.7415,8991,076,93377,403Feb 02 05:59 PM
Noblett KarenChief Medical OfficerJan 31 '24Sale67.7411,288764,60334,428Feb 02 05:59 PM
Keese Kari LeighChief Financial OfficerJan 31 '24Sale67.743,489236,33143,323Feb 02 05:59 PM
Noblett KarenChief Medical OfficerJan 08 '24Sale69.0015,9991,103,96118,216Jan 10 08:00 PM
Noblett KarenChief Medical OfficerDec 28 '23Sale63.287,051446,17734,215Dec 28 07:17 PM
Noblett KarenChief Medical OfficerDec 26 '23Sale63.0094959,78741,266Dec 28 07:17 PM
Dearen Danny L.President & CFOSep 29 '23Option Exercise0.0011,250031,452Oct 03 07:37 PM
Dearen Danny L.President & CFOSep 29 '23Sale56.877,675436,49023,777Oct 03 07:37 PM
Ford Alfred J JrChief Commercial OfficerAug 15 '23Sale62.3414,769920,67134,565Aug 17 07:47 PM
Ford Alfred J JrChief Commercial OfficerJul 28 '23Sale62.011,50093,02149,334Aug 01 08:01 PM
Dearen Danny L.President & CFOMay 26 '23Sale49.467,999395,6469,202May 31 08:01 PM